{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:42:40Z","timestamp":1781595760396,"version":"3.54.5"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40291-024-00705-1","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T03:01:50Z","timestamp":1711594910000},"page":"239-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia"],"prefix":"10.1007","volume":"28","author":[{"given":"Jeong Hyeon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-0820","authenticated-orcid":false,"given":"Jeong Pil","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"issue":"2","key":"705_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41431-020-00742-4","volume":"29","author":"I Garagiola","year":"2021","unstructured":"Garagiola I, et al. X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers. Eur J Hum Genet. 2021;29(2):241\u20139.","journal-title":"Eur J Hum Genet"},{"key":"705_CR2","doi-asserted-by":"crossref","unstructured":"Castaman G, et al. Mild and moderate hemophilia a: neglected conditions, still with unmet needs. MDPI; 2023. p. 1368.","DOI":"10.3390\/jcm12041368"},{"issue":"8","key":"705_CR3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7326\/M19-1208","volume":"171","author":"A Iorio","year":"2019","unstructured":"Iorio A, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540\u20136.","journal-title":"Ann Intern Med"},{"issue":"7","key":"705_CR4","first-page":"632","volume":"24","author":"T Thorat","year":"2018","unstructured":"Thorat T, Neumann PJ, Chambers JD. Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia. J Manag Care Spec Pharm. 2018;24(7):632\u201342.","journal-title":"J Manag Care Spec Pharm"},{"key":"705_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/JBM.S291536","volume":"14","author":"A Ndoumba-Mintya","year":"2023","unstructured":"Ndoumba-Mintya A, et al. Optimizing haemophilia care in resource-limited countries: current challenges and future prospects. J Blood Med. 2023;14:141\u20136.","journal-title":"J Blood Med."},{"key":"705_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12288-012-0209-0","volume":"30","author":"HE Castro","year":"2014","unstructured":"Castro HE, et al. The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review. Indian J Hematol Blood Transfus. 2014;30:1\u201311.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"3","key":"705_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12288-018-1054-6","volume":"35","author":"S Roy","year":"2019","unstructured":"Roy S, De AK. Effect of prophylactic management of hemophilia on bleeding episodes. Indian J Hematol Blood Transfus. 2019;35(3):496\u2013501.","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"5","key":"705_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41587-023-01775-y","volume":"41","author":"J Hodgson","year":"2023","unstructured":"Hodgson J. Drug pipeline 1Q23\u2014everything everywhere all over the place. Nat Biotechnol. 2023;41(5):591\u20133.","journal-title":"Nat Biotechnol"},{"key":"705_CR9","unstructured":"Administration, U.F.a.D. ALPROLIX\u00ae coagulation factor IX (recombinant), Fc fusion protein. 2014."},{"key":"705_CR10","unstructured":"Administration, U.F.a.D. ELOCTATE\u00ae [antihemophilic factor (recombinant), Fc fusion protein] lyophilized powder for solution for intravenous injection. 2014."},{"key":"705_CR11","doi-asserted-by":"crossref","unstructured":"Meeks SL, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. In: Hematology 2014, the American Society of Hematology Education Program Book, vol 2016, no 1. 2016. p. 657\u2013662.","DOI":"10.1182\/asheducation-2016.1.657"},{"issue":"R1","key":"705_CR12","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1093\/hmg\/ddz157","volume":"28","author":"P Batty","year":"2019","unstructured":"Batty P, Lillicrap D. Advances and challenges for hemophilia gene therapy. Hum Mol Genet. 2019;28(R1):R95\u2013101.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"705_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, et al. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317\u201334.","journal-title":"BioDrugs"},{"issue":"3","key":"705_CR14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"HC Verdera","year":"2020","unstructured":"Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28(3):723\u201346.","journal-title":"Mol Ther"},{"key":"705_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/BTT.S326422","volume":"15","author":"M Asmamaw","year":"2021","unstructured":"Asmamaw M, Zawdie B. Mechanism and applications of CRISPR\/Cas-9-mediated genome editing. Biol Targets Ther. 2021;15:353\u201361.","journal-title":"Biol Targets Ther"},{"key":"705_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","volume":"342","author":"EA Taha","year":"2022","unstructured":"Taha EA, Lee J, Hotta A. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges. J Control Release. 2022;342:345\u201361.","journal-title":"J Control Release"},{"issue":"6","key":"705_CR17","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","volume":"19","author":"P Kazemian","year":"2022","unstructured":"Kazemian P, et al. Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components. Mol Pharm. 2022;19(6):1669\u201386.","journal-title":"Mol Pharm"},{"key":"705_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/B978-0-12-800148-6.00002-X","volume":"88","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Huang L. Lipid nanoparticles for gene delivery. Adv Genet. 2014;88:13\u201336.","journal-title":"Adv Genet"},{"key":"705_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","volume":"74","author":"BJ Samelson-Jones","year":"2023","unstructured":"Samelson-Jones BJ, George LA. Adeno-associated virus gene therapy for hemophilia. Annu Rev Med. 2023;74:231\u201347.","journal-title":"Annu Rev Med"},{"issue":"51\u201352","key":"705_CR20","first-page":"887","volume":"119","author":"W Miesbach","year":"2022","unstructured":"Miesbach W, et al. Gene therapy for hemophilia\u2014opportunities and risks. Dtsch Arztebl Int. 2022;119(51\u201352):887.","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"705_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-021-00760-4","volume":"28","author":"D Okaygoun","year":"2021","unstructured":"Okaygoun D, et al. Advances in the management of haemophilia: emerging treatments and their mechanisms. J Biomed Sci. 2021;28(1):1\u201313.","journal-title":"J Biomed Sci"},{"issue":"5","key":"705_CR22","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/cells12050785","volume":"12","author":"SS Issa","year":"2023","unstructured":"Issa SS, et al. Various AAV serotypes and their applications in gene therapy: an overview. Cells. 2023;12(5):785.","journal-title":"Cells"},{"issue":"8","key":"705_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe SW, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706\u201318.","journal-title":"N Engl J Med"},{"issue":"17","key":"705_CR24","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","volume":"361","author":"P Simioni","year":"2009","unstructured":"Simioni P, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361(17):1671\u20135.","journal-title":"N Engl J Med"},{"key":"705_CR25","doi-asserted-by":"crossref","unstructured":"Pittman DD, et al. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. 1993.","DOI":"10.1182\/blood.V81.11.2925.bloodjournal81112925"},{"issue":"6","key":"705_CR26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1006\/mthe.2002.0607","volume":"5","author":"H Chao","year":"2002","unstructured":"Chao H, et al. Expression of human factor VIII by splicing between dimerized AAV vectors. Mol Ther. 2002;5(6):716\u201322.","journal-title":"Mol Ther"},{"issue":"5","key":"705_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ymthe.2017.03.033","volume":"25","author":"AW Nienhuis","year":"2017","unstructured":"Nienhuis AW, Nathwani AC, Davidoff AM. Gene therapy for hemophilia. Mol Ther. 2017;25(5):1163\u20137.","journal-title":"Mol Ther"},{"issue":"1","key":"705_CR28","doi-asserted-by":"publisher","first-page":"16838","DOI":"10.1038\/s41598-019-53198-y","volume":"9","author":"H Chen","year":"2019","unstructured":"Chen H, et al. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII. Sci Rep. 2019;9(1):16838.","journal-title":"Sci Rep"},{"issue":"8","key":"705_CR29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med. 2023;388(8):694\u2013705.","journal-title":"N Engl J Med"},{"key":"705_CR30","doi-asserted-by":"crossref","unstructured":"High-dose AAV gene therapy deaths. Nat Biotechnol. 2020;38(8):910.","DOI":"10.1038\/s41587-020-0642-9"},{"key":"705_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1134\/S0026893323040209","volume":"57","author":"M Zhang","year":"2023","unstructured":"Zhang M, Liu X, Zhang C. Random integration analysis of recombinant adeno-associated virus 6 packaged in Sf9 insect cells. Mol Biol. 2023;57:1\u201311.","journal-title":"Mol Biol"},{"key":"705_CR32","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","volume":"30","author":"DE Sabatino","year":"2022","unstructured":"Sabatino DE, et al. Evaluating the state of the science for adeno-associated virus (AAV) integration: an integrated perspective. Mol Ther. 2022;30:2646\u201363.","journal-title":"Mol Ther"},{"issue":"Supplement 1","key":"705_CR33","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1182\/blood-2023-188383","volume":"142","author":"JH McIntosh","year":"2023","unstructured":"McIntosh JH, et al. Long-term persistence of antibodies to adeno-associated viral vectors following gene therapy with scAAV8-LP1-Fixco. Blood. 2023;142(Supplement 1):2255\u20132255.","journal-title":"Blood"},{"issue":"21","key":"705_CR34","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","volume":"385","author":"LA George","year":"2021","unstructured":"George LA, et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia A. N Engl J Med. 2021;385(21):1961\u201373.","journal-title":"N Engl J Med"},{"issue":"11","key":"705_CR35","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013\u201325.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"705_CR36","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1182\/blood-2021-148651","volume":"138","author":"N Visweshwar","year":"2021","unstructured":"Visweshwar N, et al. Updated results of the Alta study, a phase 1\/2 study of giroctocogene fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia a. Blood. 2021;138(Supplement 1):564\u2013564.","journal-title":"Blood"},{"issue":"13","key":"705_CR37","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","volume":"127","author":"N Uchida","year":"2016","unstructured":"Uchida N, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127(13):1633\u201341.","journal-title":"Blood"},{"issue":"10","key":"705_CR38","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","volume":"18","author":"T Kitazawa","year":"2012","unstructured":"Kitazawa T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570\u20134.","journal-title":"Nat Med"},{"issue":"2","key":"705_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40265-018-0861-2","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott LJ, Kim ES. Emicizumab-kxwh: First Global Approval. Drugs. 2018;78(2):269\u201374.","journal-title":"Drugs"},{"issue":"9","key":"705_CR40","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809\u201318.","journal-title":"N Engl J Med"},{"issue":"14","key":"705_CR41","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood.2020010331","volume":"138","author":"H Ostergaard","year":"2021","unstructured":"Ostergaard H, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138(14):1258\u201368.","journal-title":"Blood"},{"issue":"6","key":"705_CR42","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/jth.15682","volume":"20","author":"B Lauritzen","year":"2022","unstructured":"Lauritzen B, et al. A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: results from safety studies in cynomolgus monkeys. J Thromb Haemost. 2022;20(6):1312\u201324.","journal-title":"J Thromb Haemost"},{"issue":"15","key":"705_CR43","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","volume":"79","author":"HA Blair","year":"2019","unstructured":"Blair HA. Emicizumab: a review in haemophilia A. Drugs. 2019;79(15):1697\u2013707.","journal-title":"Drugs"},{"issue":"6","key":"705_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102181","volume":"7","author":"P Persson","year":"2023","unstructured":"Persson P, et al. Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults. Res Pract Thromb Haemost. 2023;7(6): 102181.","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"705_CR45","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/j.1365-2516.2008.01830.x","volume":"14","author":"MM Patnaik","year":"2008","unstructured":"Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 2008;14(6):1229\u201339.","journal-title":"Haemophilia"},{"issue":"1","key":"705_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/GIM.0b013e3181faa0f2","volume":"13","author":"JL Kujovich","year":"2011","unstructured":"Kujovich JL. Factor v Leiden thrombophilia. Genet Med. 2011;13(1):1\u201316.","journal-title":"Genet Med"},{"key":"705_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/8872346","volume":"2023","author":"S Alqarni","year":"2023","unstructured":"Alqarni S, Alqarni B, Alsultan A. Antithrombin deficiency is associated with a novel homozygous detrimental mutation in SERPINC1 gene in a Saudi female. Case Rep Med. 2023;2023:1\u20134.","journal-title":"Case Rep Med"},{"issue":"1","key":"705_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12959-022-00443-6","volume":"21","author":"H-L Wang","year":"2023","unstructured":"Wang H-L, et al. Identification and characterization of two SERPINC1 mutations causing congenital antithrombin deficiency. Thromb J. 2023;21(1):1\u201316.","journal-title":"Thromb J"},{"issue":"4","key":"705_CR49","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jvscit.2017.11.002","volume":"3","author":"W Xie","year":"2017","unstructured":"Xie W, Liu Z, Chen B. Protein C deficiency resulting from two mutations in PROC presenting with recurrent venous thromboembolism. J Vasc Surg Cases Innov Tech. 2017;3(4):254\u20136.","journal-title":"J Vasc Surg Cases Innov Tech"},{"issue":"11","key":"705_CR50","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/ajh.21542","volume":"84","author":"A Kentsis","year":"2009","unstructured":"Kentsis A, et al. Venous thrombosis associated with gene deletion of tissue factor pathway inhibitor. Am J Hematol. 2009;84(11):775.","journal-title":"Am J Hematol"},{"issue":"1","key":"705_CR51","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/hematology.2021000253","volume":"2021","author":"P Ellsworth","year":"2021","unstructured":"Ellsworth P, Ma A. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? Hematology. 2021;2021(1):219\u201325.","journal-title":"Hematology"},{"issue":"5","key":"705_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28934","volume":"68","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Weyand AC, Shavit JA. Novel treatments for hemophilia through rebalancing of the coagulation cascade. Pediatr Blood Cancer. 2021;68(5): e28934.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"705_CR53","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2216455","volume":"389","author":"T Matsushita","year":"2023","unstructured":"Matsushita T, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023;389(9):783\u201394.","journal-title":"N Engl J Med"},{"issue":"2","key":"705_CR54","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.18495","volume":"200","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results. Br J Haematol. 2023;200(2):240\u20138.","journal-title":"Br J Haematol"},{"issue":"5","key":"705_CR55","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","volume":"24","author":"SG Polderdijk","year":"2017","unstructured":"Polderdijk SG, Baglin TP, Huntington JA. Targeting activated protein C to treat hemophilia. Curr Opin Hematol. 2017;24(5):446.","journal-title":"Curr Opin Hematol"},{"issue":"S3","key":"705_CR56","doi-asserted-by":"publisher","first-page":"e643526e","DOI":"10.1097\/01.HS9.0000968124.64352.6e","volume":"7","author":"G Kenet","year":"2023","unstructured":"Kenet G, et al. S303: a phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran in people with haemophilia A OR B who have switched from prior clotting factor concentrate or bypassing agent prophylaxis. HemaSphere. 2023;7(S3):e643526e.","journal-title":"HemaSphere"},{"issue":"9","key":"705_CR57","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.3390\/ijms19092721","volume":"19","author":"BX Ho","year":"2018","unstructured":"Ho BX, et al. In vivo genome editing as a therapeutic approach. Int J Mol Sci. 2018;19(9):2721.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"705_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"H Li","year":"2020","unstructured":"Li H, et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5(1):1.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"705_CR59","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41392-021-00642-z","volume":"6","author":"N Meng","year":"2021","unstructured":"Meng N, Grimm D. Membrane-destabilizing ionizable phospholipids: Novel components for organ-selective mRNA delivery and CRISPR\u2013Cas gene editing. Signal Transduct Target Ther. 2021;6(1):206.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"705_CR60","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394.","journal-title":"Nat Rev Mater"},{"issue":"3","key":"705_CR61","doi-asserted-by":"publisher","first-page":"eabj6901","DOI":"10.1126\/sciadv.abj6901","volume":"8","author":"JP Han","year":"2022","unstructured":"Han JP, et al. In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy. Sci Adv. 2022;8(3):eabj6901.","journal-title":"Sci Adv"},{"issue":"1","key":"705_CR62","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","volume":"12","author":"E Kenjo","year":"2021","unstructured":"Kenjo E, et al. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat Commun. 2021;12(1):7101.","journal-title":"Nat Commun"},{"key":"705_CR63","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jconrel.2020.07.014","volume":"326","author":"IV Zelepukin","year":"2020","unstructured":"Zelepukin IV, et al. Fast processes of nanoparticle blood clearance: Comprehensive study. J Control Release. 2020;326:181\u201391.","journal-title":"J Control Release"},{"issue":"9","key":"705_CR64","doi-asserted-by":"publisher","first-page":"eabf4398","DOI":"10.1126\/sciadv.abf4398","volume":"7","author":"M Kim","year":"2021","unstructured":"Kim M, et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci Adv. 2021;7(9):eabf4398.","journal-title":"Sci Adv"},{"issue":"8","key":"705_CR65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116271119","volume":"119","author":"M Qiu","year":"2022","unstructured":"Qiu M, et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci. 2022;119(8): e2116271119.","journal-title":"Proc Natl Acad Sci"},{"key":"705_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.68","volume":"5","author":"G Basha","year":"2016","unstructured":"Basha G, et al. Lipid nanoparticle delivery of siRNA to osteocytes leads to effective silencing of SOST and inhibition of sclerostin in vivo. Mol Ther Nucleic Acids. 2016;5: e363.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"705_CR67","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang X, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2023;18(1):265\u201391.","journal-title":"Nat Protoc"},{"issue":"10","key":"705_CR68","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41587-023-01679-x","volume":"41","author":"B Li","year":"2023","unstructured":"Li B, et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat Biotechnol. 2023;41(10):1410\u20135.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"705_CR69","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.3390\/cimb44100341","volume":"44","author":"R Mashima","year":"2022","unstructured":"Mashima R, Takada S. Lipid nanoparticles: a novel gene delivery technique for clinical application. Curr Issues Mol Biol. 2022;44(10):5013\u201327.","journal-title":"Curr Issues Mol Biol"},{"issue":"12","key":"705_CR70","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nbt.4005","volume":"35","author":"H Yin","year":"2017","unstructured":"Yin H, et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat Biotechnol. 2017;35(12):1179\u201387.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"705_CR71","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nbt.3471","volume":"34","author":"H Yin","year":"2016","unstructured":"Yin H, et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016;34(3):328\u201333.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"705_CR72","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/biom10060839","volume":"10","author":"BH Yip","year":"2020","unstructured":"Yip BH. Recent advances in CRISPR\/Cas9 delivery strategies. Biomolecules. 2020;10(6):839.","journal-title":"Biomolecules"},{"issue":"8","key":"705_CR73","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","volume":"70","author":"J Gee","year":"2021","unstructured":"Gee J, et al. First month of COVID-19 vaccine safety monitoring\u2014United States, December 14, 2020\u2013January 13, 2021. Morb Mortal Wkly Rep. 2021;70(8):283.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"12","key":"705_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen S, et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24(12): 103479.","journal-title":"iScience"},{"issue":"6","key":"705_CR75","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.ymthe.2022.04.011","volume":"30","author":"SM Moghimi","year":"2022","unstructured":"Moghimi SM, Simberg D. Pro-inflammatory concerns with lipid nanoparticles. Mol Ther. 2022;30(6):2109\u201310.","journal-title":"Mol Ther"},{"issue":"10","key":"705_CR76","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","volume":"55","author":"Y Lee","year":"2023","unstructured":"Lee Y, et al. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp Mol Med. 2023;55(10):2085\u201396.","journal-title":"Exp Mol Med"},{"issue":"4","key":"705_CR77","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen S, et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022;23(4):532\u201342.","journal-title":"Nat Immunol"},{"issue":"6","key":"705_CR78","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493\u2013502.","journal-title":"N Engl J Med"},{"issue":"5","key":"705_CR79","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.anai.2023.08.106","volume":"131","author":"D Cohn","year":"2023","unstructured":"Cohn D, et al. CRISPR\/CAS9 editing of KLKB1 in hereditary angioedema patients: updated results: from a phase 1 study. Ann Allergy Asthma Immunol. 2023;131(5):S32.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"705_CR80","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","volume":"147","author":"RG Lee","year":"2023","unstructured":"Lee RG, et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation. 2023;147(3):242\u201353.","journal-title":"Circulation"},{"key":"705_CR81","unstructured":"H, B. First patient dosed with HIV gene therapy. European Pharmaceutical Review. 2022."},{"issue":"2","key":"705_CR82","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","volume":"25","author":"ML Maeder","year":"2019","unstructured":"Maeder ML, et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019;25(2):229\u201333.","journal-title":"Nat Med"},{"issue":"8","key":"705_CR83","first-page":"934","volume":"64","author":"L Shi","year":"2023","unstructured":"Shi L, et al. Development of an RNA targeting based gene therapy product for neovascular age-related macular degeneration (nAMD). Invest Ophthalmol Vis Sci. 2023;64(8):934\u2013934.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"705_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1232188","author":"M Saito","year":"2023","unstructured":"Saito M, et al. Recent advances in the understanding of cilia mechanisms and their applications as therapeutic targets. Front Mol Biosci. 2023. https:\/\/doi.org\/10.3389\/fmolb.2023.1232188.","journal-title":"Front Mol Biosci."},{"key":"705_CR85","unstructured":"Meloni I. Gene editing as a therapeutic approach for Rett Syndrome (MECPer-3D). 2023. https:\/\/classic.clinicaltrials.gov\/show\/NCT05740761."},{"issue":"5","key":"705_CR86","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.anai.2022.08.536","volume":"129","author":"H Longhurst","year":"2022","unstructured":"Longhurst H, et al. In vivo CRISPR\/Cas9 editing of KLKB1 in patients with hereditary angioedema: a first-in-human study. Ann Allergy Asthma Immunol. 2022;129(5):S10\u20131.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"705_CR87","doi-asserted-by":"publisher","first-page":"AB147","DOI":"10.1016\/j.jaci.2020.12.531","volume":"147","author":"J Seitzer","year":"2021","unstructured":"Seitzer J. NTLA-2002: CRISPR\/Cas9-mediated gene knockout of KLKB1 to treat hereditary angioedema. J Allergy Clin Immunol. 2021;147(2):AB147.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"705_CR88","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020401118","volume":"118","author":"M Qiu","year":"2021","unstructured":"Qiu M, et al. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3. Proc Natl Acad Sci. 2021;118(10): e2020401118.","journal-title":"Proc Natl Acad Sci"},{"issue":"47","key":"705_CR89","doi-asserted-by":"publisher","first-page":"eabc9450","DOI":"10.1126\/sciadv.abc9450","volume":"6","author":"D Rosenblum","year":"2020","unstructured":"Rosenblum D, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. 2020;6(47):eabc9450.","journal-title":"Sci Adv"},{"issue":"2","key":"705_CR90","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.tibtech.2017.11.006","volume":"36","author":"Z Glass","year":"2018","unstructured":"Glass Z, et al. Engineering the delivery system for CRISPR-based genome editing. Trends Biotechnol. 2018;36(2):173\u201385.","journal-title":"Trends Biotechnol"},{"issue":"6","key":"705_CR91","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.molmed.2021.03.003","volume":"27","author":"KL Swingle","year":"2021","unstructured":"Swingle KL, Hamilton AG, Mitchell MJ. Lipid nanoparticle-mediated delivery of mRNA therapeutics and vaccines. Trends Mol Med. 2021;27(6):616\u20137.","journal-title":"Trends Mol Med"},{"issue":"6","key":"705_CR92","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/hep.20214","volume":"39","author":"N Fausto","year":"2004","unstructured":"Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology. 2004;39(6):1477\u201387.","journal-title":"Hepatology"},{"issue":"2","key":"705_CR93","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0896-6273(03)00632-9","volume":"40","author":"S-I Ohnuma","year":"2003","unstructured":"Ohnuma S-I, Harris WA. Neurogenesis and the cell cycle. Neuron. 2003;40(2):199\u2013208.","journal-title":"Neuron"},{"key":"705_CR94","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.omtm.2020.06.025","volume":"18","author":"Q Wang","year":"2020","unstructured":"Wang Q, et al. CRISPR-Cas9-mediated in vivo gene integration at the albumin locus recovers hemostasis in neonatal and adult hemophilia B mice. Mol Ther Methods Clin Dev. 2020;18:520\u201331.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"705_CR95","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.omtn.2022.08.002","volume":"29","author":"JH Lee","year":"2022","unstructured":"Lee JH, et al. Genome editing-mediated knock-in of therapeutic genes ameliorates the disease phenotype in a model of hemophilia. Mol Ther Nucl Acids. 2022;29:551\u201362.","journal-title":"Mol Ther Nucl Acids"},{"issue":"15\u201316","key":"705_CR96","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1089\/hum.2020.217","volume":"31","author":"PB Shieh","year":"2020","unstructured":"Shieh PB, et al. Re: \u201cMoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d by Wilson and Flotte. Hum Gene Ther. 2020;31(15\u201316):787\u2013787.","journal-title":"Hum Gene Ther"},{"issue":"4 Suppl 1","key":"705_CR97","first-page":"7","volume":"27","author":"H-R Huang","year":"2019","unstructured":"Huang H-R, et al. CRISPR\/Cas9-mediated targeted insertion of human F9 achieves therapeutic circulating protein levels in mice and non-human primates. Mol Ther. 2019;27(4 Suppl 1):7.","journal-title":"Mol Ther"},{"key":"705_CR98","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.omtn.2023.03.008","volume":"32","author":"JH Lee","year":"2023","unstructured":"Lee JH, et al. In vivo genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector. Mol Ther Nucl Acids. 2023;32:161\u201372.","journal-title":"Mol Ther Nucl Acids"},{"key":"705_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.102050","volume":"34","author":"JP Han","year":"2023","unstructured":"Han JP, et al. In vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice. Mol Ther Nucl Acids. 2023;34: 102050.","journal-title":"Mol Ther Nucl Acids"},{"key":"705_CR100","first-page":"1","volume":"42","author":"C Sheridan","year":"2023","unstructured":"Sheridan C. The world\u2019s first CRISPR therapy is approved: who will receive it? Nat Biotechnol. 2023;42:1\u20133.","journal-title":"Nat Biotechnol"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00705-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-024-00705-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00705-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T09:48:06Z","timestamp":1714729686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-024-00705-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1007\/s40291-024-00705-1","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"assertion":[{"value":"13 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JHL and JPH declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JHL and JPH drafted the manuscript. JHL prepared the table. JPH prepared all figures. JHL and JPH revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}